ZyVersa Therapeutics, Inc. (ZVSA)
After hours:
| Previous close | 5.28 |
| Open | 5.18 |
| Bid | 5.12 x 100 |
| Ask | 5.53 x 100 |
| Day's range | 5.16 - 5.44 |
| 52-week range | 4.44 - 180.25 |
| Volume | |
| Avg. volume | 415,773 |
| Market cap | 4.078M |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1,089.70 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 70.00 |
GlobeNewswireZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates that multiple inflammasome triggers (NLRP1 and pyrin) govern the inflammatory response in Alzheimer’s Disease (AD), and that release of inflammasome laden extracellular vesicles (EV) into the blood induce significant inflammation in cardiovascular cells.ZyVersa is developing Inflammasome ASC Inhibitor IC 100 to inhibit multiple types of
- GlobeNewswire
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published data show that inhibiting the NLRP3 inflammasome pathway significantly reduces atherosclerotic lesions and improves hyperglycemic-induced plaque instability.ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome ASC and ASC specks from multiple types of inflammasomes, including NLRP3, t
- GlobeNewswire
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical program nearing completion, with planned Investigational New Drug (IND) submission Q4-2024, and Phase 1 clinical trial initiation shortly thereafter.Inflammasome ASC Inhibitor IC 100 preclinical research funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) nearing completion, with potenti
